Morningstar says another CagriSema miss pressures Novo high-dose plan

The wire

1. 01Morningstar called a further CagriSema trial result disappointing, adding pressure to Novo Nordisk's strategy of pushing higher doses of the cagrilintide plus semaglutide combination.
2. 02Amylin-analog combinations are the closest challenger to tirzepatide, so weaker data shapes what compounders, prescribers and payers can expect from the next obesity launch.
3. 03This is analyst commentary rather than a company release; full trial detail and any regulatory consequence remain with Novo Nordisk.

From the source

Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy